How much does a bottle of Seladelpar cost?

Seladelpar is a new type of targeted drug, mainly used to treat primary biliary cholangitis (PBC), especially for patients who have poor response or intolerance to the traditional first-line drug ursodeoxycholic acid (UDCA). Its mechanism of action is a selective PPARδ receptor agonist, which reduces cholestasis and liver cell damage by regulating liver metabolism and anti-inflammatory signaling pathways, thereby slowing down disease progression and improving serum bilirubin and liver function indicators. Clinical studies have shown that Siladepa can effectively improve patients' biochemical indicators and may delay liver fibrosis and cholestasis-related complications in long-term use.

Currently, Siladepa is not available on the market in China, so it cannot be purchased through formal channels in China. In overseas markets, the original drug is sold in the format of 10mg*30 capsules, and each box may cost more than 10,000 US dollars. The specific price will vary due to exchange rate fluctuations and different import channels. Since the drug is an oral capsule, the dosage is usually once a day, and the treatment cycle depends on the patient's condition and doctor's evaluation, so the cost of long-term medication is higher.

At the same time, a generic version has also appeared in overseas markets, also in the specification of 10mg*30 pills and the price per box is about RMB 3,600. The active ingredients of these generic drugs are basically the same as those of the original drugs, and their efficacy and safety are considered to be comparable to those of the original drugs in most studies. However, it is still recommended to obtain them through regular pharmacies and legal channels to ensure drug quality and safety in clinical use. For patients, the choice between original drugs or generic drugs must be based on their own financial situation, doctor's advice, and considerations of drug efficacy and long-term safety.

In summary, as a new targeted drug for the treatment of primary biliary cholangitis, Siladepa has potential in improving liver function indicators, reducing disease progression, and improving quality of life.

Reference materials:https://go.drugbank.com/drugs/DB12390